keyword
MENU ▼
Read by QxMD icon Read
search

ocriplasmin

keyword
https://www.readbyqxmd.com/read/29141079/visual-function-response-to-ocriplasmin-for-the-treatment-of-vitreomacular-traction-and-macular-hole-the-oasis-study
#1
Benedicte Lescrauwaet, Luc Duchateau, Thomas Verstraeten, Timothy L Jackson
Purpose: To assess the effect of ocriplasmin on visual function response (VFR) measured using visual acuity (VA) and vision-related quality of life, and to quantify the association between release of vitreomacular adhesion (VMA) at day 28 and VFR. Methods: Prespecified analysis of secondary endpoints from a randomized controlled trial. Of 220 participants with symptomatic VMA/vitreomacular traction (VMT), including VMT associated with a macular hole up to 400 μm, 146 received a single intravitreal injection of 125 μg ocriplasmin and 74 a sham injection...
November 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29135889/comparison-of-resolution-of-vitreomacular-traction-after-ocriplasmin-treatment-or-vitrectomy
#2
Paula Scholz, Vasilena Sitnilska, Jelka Hess, Matthias Becker, Stephan Michels, Sascha Fauser
PURPOSE: To compare the functional and morphologic outcome of patients with vitreomacular traction (VMT) treated with either ocriplasmin treatment or vitrectomy. METHODS: Retrospective case series of patients treated with ocriplasmin or vitrectomy for VMT. OUTCOME MEASURES: resolution of VMT, change in outer retinal thickness, integrity of ellipsoid zone, subretinal fluid formation, and best-corrected visual acuity 2 weeks and 4 months after treatment...
November 9, 2017: Retina
https://www.readbyqxmd.com/read/29111823/surgical-results-in-ocriplasmin-candidates-with-symptomatic-vitreomacular-traction-syndrome
#3
Dario H Vasquez, Juan C Altamirano, Angel Casaus, Rodrigo A Del Valle, Roberto Gonzalez, Alejandro Gonzalez-De La Rosa, Jose Navarro-Partida, Martin A Vasquez, Arturo Santos
PURPOSE: To report surgical outcomes in a series of cases with symptomatic vitreomacular traction that met MIVI-TRUST (Microplasmin for intravitreous injection-traction release without surgical treatment) criteria for ocriplasmin use who underwent primary 25-gauge vitrectomy. MATERIALS AND METHODS: A single-center retrospective chart review study was performed in patients who underwent primary 25-gauge vitrectomy for symptomatic vitreomacular traction (VTM) from January 2013 through January 2016...
November 7, 2017: Current Eye Research
https://www.readbyqxmd.com/read/29089354/calculating-the-individual-probability-of-successful-ocriplasmin-treatment-in-eyes-with-vmt-syndrome-a-multivariable-prediction-model-from-the-export-study
#4
Christoph Paul, Christine Heun, Hans-Helge Müller, Hans Hoerauf, Nicolas Feltgen, Joachim Wachtlin, Hakan Kaymak, Stefan Mennel, Michael Janusz Koss, Sascha Fauser, Mathias M Maier, Ricarda G Schumann, Simone Mueller, Petrus Chang, Steffen Schmitz-Valckenberg, Sara Kazerounian, Peter Szurman, Albrecht Lommatzsch, Thomas Bertelmann
BACKGROUND/AIMS: To evaluate predictive factors for the treatment success of ocriplasmin and to use these factors to generate a multivariate model to calculate the individual probability of successful treatment. METHODS: Data were collected in a retrospective, multicentre cohort study. Patients with vitreomacular traction (VMT) syndrome without a full-thickness macular hole were included if they received an intravitreal injection (IVI) of ocriplasmin. Five factors (age, gender, lens status, presence of epiretinal membrane (ERM) formation and horizontal diameter of VMT) were assessed on their association with VMT resolution...
October 31, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29040800/ocriplasmin-for-symptomatic-vitreomacular-adhesion
#5
REVIEW
James E Neffendorf, Varo Kirthi, Edward Pringle, Timothy L Jackson
BACKGROUND: Symptomatic vitreomacular adhesion (sVMA) is a recognised cause of visual loss and by tradition has been managed by pars plana vitrectomy (PPV). A less invasive alternative to surgery in some people is enzymatic vitreolysis, using an intravitreal injection of ocriplasmin. OBJECTIVES: To assess the efficacy and safety of ocriplasmin compared to no treatment, sham or placebo for the treatment of sVMA. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2017, Issue 1), MEDLINE Ovid (1946 to 24 February 2017), Embase Ovid (1947 to 24 February 2017), PubMed (1946 to 24 February 2017), the ISRCTN registry (www...
October 17, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28954271/impact-of-preinjection-spectral-domain-optical-coherence-tomography-findings-in-the-use-of-intravitreal-ocriplasmin-in-a-clinical-setting
#6
Christian Wertheimer, Christos Haritoglou, Peter Laubichler, Armin Wolf, Kathrin Kaessmann, Ricarda G Schumann, Siegfried Priglinger, Wolfgang J Mayer
PURPOSE: To investigate the impact of spectral domain optical coherence tomography (SD-OCT) morphological predictive markers on visual acuity and outcome using ocriplasmin for macular hole and vitreomacular traction syndrome. METHODS: A series of 40 patients in a retrospective study received intravitreal ocriplasmin. The primary endpoint was defined as morphological resolution of vitreomacular traction or closure of a macular hole. We analyzed the impact of pre- and postinjection SD-OCT findings on the outcome and visual acuity...
September 28, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28857483/intravitreal-gas-for-symptomatic-vitreomacular-adhesion-a-synthesis-of-the-literature
#7
REVIEW
James E Neffendorf, Andrew R H Simpson, David H W Steel, Riti Desai, Dominic A McHugh, Edward Pringle, Timothy L Jackson
Symptomatic vitreomacular adhesion (sVMA) is defined as visual loss secondary to foveal damage from vitreomacular traction (VMT) and includes isolated VMT, impending macular hole (MH), and full-thickness MH with persisting vitreous attachment. Management options include pars plana vitrectomy (PPV), intravitreal ocriplasmin, intravitreal gas injection or observation. This synthesis of the literature aimed to assess the safety and efficacy of intravitreal gas for sVMA. Articles describing patients with VMT or MH treated with intravitreal expansile gas were selected by systematic literature review using MEDLINE, EMBASE, and the Cochrane Database of Controlled Trials (CENTRAL) up to September 2016...
August 31, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28791829/intravitreal-ocriplasmin-a-breakthrough-in-the-treatment-of-vitreomacular-traction
#8
REVIEW
Anna E Mec-Słomska, Joanna Adamiec-Mroczek, Ewa Kuźmicz, Marta Misiuk-Hojło
Vitreoretinal interface pathologies, such as vitreomacular traction syndrome, epiretinal membranes and macular holes are sight-threatening conditions and one of the important causes of vision defects and vision loss. To this date, vigilance with observation of how the vitreomacular traction resolves, or vitreoretinal surgery in more severe cases, were the only treatment options. Recent rapid progress in ophthalmology, especially in diagnostic and visualization techniques, provided better insight into the mechanisms taking place on the vitreoretinal surface, which enabled a more accurate selection of treatment options...
May 2017: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/28767551/ocriplasmin-for-vitreomacular-traction-looking-outside-the-macula-a-wide-field-optical-coherence-tomography-study
#9
Matteo G Cereda, Chiara Preziosa, Isabella DʼAgostino, Mariano Cozzi, Ferdinando Bottoni, Marco Pellegrini, Andrea Giani, Giovanni Staurenghi
PURPOSE: To evaluate baseline features and morphologic changes of vitreoretinal adhesion and outer retinal layers outside the macula after intravitreal ocriplasmin injection. To study the relation between vitreous detachment and attenuation of retinal outer segments signal. METHODS: Retrospective cases series of 15 eyes. Each eye was scanned with the 55° wide-field optical coherence tomography lens in 6 different locations, three horizontal B-scan (central, temporal, and nasal) and three vertical B-scan (central, superior, and inferior) at baseline, 1 week, 1 month, 3 months, and 6 months after injection...
August 1, 2017: Retina
https://www.readbyqxmd.com/read/28755165/assessment-of-intravitreal-ocriplasmin-treatment-for-vitreomacular-traction-in-clinical-practice
#10
Ricarda G Schumann, Julian Langer, Denise Compera, Katharina Luedtke, Markus M Schaumberger, Thomas Kreutzer, Wolfgang J Mayer, Armin Wolf, Siegfried G Priglinger
PURPOSE: To assess treatment effects following intravitreal injection of ocriplasmin for vitreomacular traction (VMT), with or without full-thickness macular hole (FTMH), in real-life setting. METHODS: This is a monocentric, retrospective, consecutive series of 82 eyes from 82 patients who underwent ocriplasmin treatment between July 2013 and December 2016. We included 57 eyes with pure VMT, 17 eyes with small FTMHs, and eight eyes with medium FTMHs. Primary outcome measures were VMT release and MH closure rates...
November 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28699051/-assessing-the-added-benefit-of-new-ophthalmic-drugs-which-additional-insights-can-be-extracted-from-the-early-benefit-assessment
#11
REVIEW
M Appelrath, G Glaeske
Until now six ophthalmic agents have undergone the German early benefit assessment according to § 35a Social Security Code (SGB) V in a total of eleven indications. Only one agent (ocriplasmin) was recognized by the Federal Joint Committee as having an added benefit based on submitted study data for a subpopulation (indication of a considerable added benefit, limited for 5 years) and another agent, idebenone, received an added benefit due to its orphan drug designation (proof of a not quantifiable added benefit, limited for 2 years)...
July 11, 2017: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/28681138/ocriplasmin-treatment-for-vitreomacular-traction-in-real-life-can-the-indication-spectrum-be-expanded
#12
Kleanthis Manousaridis, Silvia Peter-Reichart, Stefan Mennel
PURPOSE: To evaluate the efficacy of intravitreal ocriplasmin for the resolution of vitreomacular traction (VMT) with or without a full thickness macular hole (FTMH) in the clinical setting and to assess whether the indication spectrum of this treatment modality can be expanded beyond that of the MIVI-TRUST trials. METHODS: The records of patients with VMT with or without FTMH, who were treated with intravitreal ocriplasmin were reviewed. Patients were divided in two groups...
October 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28599332/-efficacy-and-safety-profile-of-ocriplasmin-treatment-an-update
#13
Denise Compera, Siegfried Priglinger, Ricarda Gisela Schumann
Pharmacological vitreolysis with ocriplasmin is an effective treatment option for eyes with vitreomacular traction. Pre-marketing and post-marketing clinical studies revealed an improvement of visual function in ocriplasmin treated eyes and showed a release of traction in up to 78% of cases. Treatment success is related to patient selection based on positive predictive factors. Adverse events, such as visual acuity loss, dyschromatopsia or photopsia are known to be self-limited in the majority of eyes. Structural outer retinal layer changes, such as ellipsoid zone disturbances or subretinal fluid accumulation on SD-OCT analysis, as well as ERG abnormalities, are transient and correlated to VMT release...
June 9, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28596997/the-charles-schepens-lecture-management-options-for-vitreomacular-traction-use-an-individualized-approach
#14
Harry W Flynn, Nidhi Relhan
PURPOSE: To present the management options for vitreomacular traction (VMT) and to recommend an individualized approach to treatment selection. DESIGN: Presented at the American Academy of Ophthalmology Annual Meeting, 2016, Chicago, October 15, 2016 (The Charles Schepens Lecture). PARTICIPANTS: None. METHODS: Review of published literature and clinical trials. MAIN OUTCOME MEASURES: Visual and anatomic outcomes of various treatment options for VMT were reviewed...
January 2017: Ophthalmology retina
https://www.readbyqxmd.com/read/28427074/enzymatic-vitreolysis-for-vitreomacular-traction-in-diabetic-retinopathy
#15
REVIEW
Stanislao Rizzo, Daniela Bacherini
Vitreomacular traction (VMT) is one of many possible factors involved in the etiology of diabetic macular edema (DME). Pharmacologic vitreoretinal separation is a potential alternative to vitrectomy for VMT in diabetic retinopathy. Small case series have been published on the use of enzymatic vitreolysis in tractional DME, and demonstrate that the enzymatic release of the posterior vitreous cortex is more likely following the injection of plasmin enzyme. Further prospective and randomized clinical trials are necessary to evaluate the clinical relevance of ocriplasmin for vitreomacular traction in diabetic retinopathy, and additional studies are needed to determine more accurately which patients might benefit most from this treatment and how often and at what concentration ocriplasmin should be administered...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28389700/the-predictability-of-ocriplasmin-treatment-effects-is-there-consensus-among-retinal-experts-results-from-the-export-study
#16
Thomas Bertelmann, Joachim Wachtlin, Stefan Mennel, Michael J Koss, Mathias M Maier, Ricarda G Schumann, Sara Kazerounian, Hanna Daniel, Steffen Schmitz-Valckenberg
PURPOSE: To evaluate the agreement and predictability of ocriplasmin treatment effects among retinal experts (raters) by assessment of retinal imaging data of eyes treated for vitreomacular traction in nine different centers in Germany and Austria. METHODS: Retrospective cohort study. Combined confocal near-infrared scanning laser ophthalmoscopy and spectral-domain optical coherence tomography images (Spectralis® device, Heidelberg Engineering GmbH, Germany) from 136 eyes of 135 subjects were reviewed by 14 raters using an internet-based grading database and a standardized questionnaire...
July 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28282697/-initial-clinical-experiences-using-ocriplasmin-for-the-treatment-of-vitreomacular-traction-with-or-without-a-macular-hole
#17
J Lenk, E Matthé, S Ventzke, L E Pillunat, D Sandner
Purpose In vitreomacular traction (VMT), there is abnormal adhesion between the vitreous cortex and the retina, especially in the fovea. Symptoms of VMT include metamorphopsia and a decrease in visual acuity. Since 2013, ocriplasmin (Jetrea®) has been approved for treatment of symptomatic vitreomacular traction with or without macular holes (≤ 400 µm). Methods We retrospectively examined twenty-three eyes of twenty-one patients who underwent intravitreal ocriplasmin treatment for symptomatic vitreomacular traction with or without macular holes...
March 10, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28282694/long-term-persistence-of-subfoveal-fluid-following-ocriplasmin-treatment-of-an-ftmh
#18
S Tschuppert, H Gerding
No abstract text is available yet for this article.
April 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28264098/intravitreally-injected-fluid-dispersion-importance-of-injection-technique
#19
Koen Willekens, Geert Reyns, Marjan Diricx, Marc Vanhove, Bernard Noppen, Walter Coudyzer, Yicheng Ni, Jean H M Feyen, Peter Stalmans
Purpose: The purpose of this study was to evaluate the dispersion of intravitreally injected solutions and investigate the influence of varying injection techniques. Methods: This was a prospective study using enucleated porcine eyes and ultra-high-resolution computed tomography (UHRCT) scanning to visualize iomeprol intravitreal dispersion. Sixty eyes were divided over 12 different groups according to the injection procedure: fast (2 seconds) or slow (10 seconds) injection speed and needle tip location (6- and 12-mm needle shaft insertion or premacular tip placement verified by indirect ophthalmoscopy)...
March 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28198785/evaluation-of-full-field-electroretinogram-reductions-after-ocriplasmin-treatment-results-of-the-oasis-trial-erg-substudy
#20
David G Birch, Matthew S Benz, Daniel M Miller, Andrew N Antoszyk, Joseph Markoff, Petra Kozma, Esmeralda Meunier, Robert C Sergott
PURPOSE: To explore a possible association between full-field electroretinograms with vitreomacular adhesion resolution and best-corrected visual acuity as part of the prospective, randomized, double-masked, sham-controlled Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) trial studying ocriplasmin. METHODS: The ERG substudy enrolled 62 of 220 OASIS subjects (randomized 2:1) and analyzed full-field electroretinograms and their association with both vitreomacular adhesion resolution and best-corrected visual acuity from baseline through Month 24...
February 14, 2017: Retina
keyword
keyword
55513
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"